Literature DB >> 22892284

Discrepancies in dermatopathology diagnoses: the role of second review policies and dermatopathology fellowship training.

Sudeep Gaudi1, J Manuel Zarandona, Stephen S Raab, Joseph C English, Drazen M Jukic.   

Abstract

BACKGROUND: Expert consultation and institutional policies mandating second review of pathologic diagnoses in the course of referral have been advocated to optimize patient care.
OBJECTIVE: We sought to investigate the rate of diagnostic discrepancies between pathologists with and without dermatopathology fellowship training.
METHODS: All available outside pathology reports were reviewed for material sent to the University of Pittsburgh Medical Center Dermatopathology Unit during 1 year. The outside diagnosis was compared with the diagnosis rendered by the referral dermatopathology service. Cases were assigned into 1 of 4 categories: melanocytic neoplasm, nonmelanocytic neoplasm, inflammatory, and other. For each case, the outside pathologist's level of dermatopathology training was noted. Any change in diagnosis resulting in significant alteration in therapy or prognosis, as dictated by the accepted standard of care, was considered a major discrepancy.
RESULTS: A total of 405 cases were reviewed. In 51 cases (13%), no preliminary diagnosis was rendered at the outside facility. The referral diagnosis differed from the outside diagnosis in 226 cases (56%), and major discrepancies were identified in 91 cases (22%). Of these 91 cases, 84 were received from outside pathologists who were not dermatopathology trained and 7 were received from pathologists with dermatopathology training. The 91 cases with major discrepancies were categorized as: 36 nonmelanocytic neoplasms (40%), 30 inflammatory (33%), 23 melanocytic neoplasms (25%), and 2 other (2%). LIMITATIONS: This was a retrospective study limited to 2 consultant dermatopathologists at an academic referral center, which typically receives and reviews select cases.
CONCLUSION: Dermatopathology fellowship training is associated with a substantial decrease in major diagnostic discrepancies. Pathologists without dermatopathology fellowship training tend to successfully identify those cases for which expert consultation is most useful.
Copyright © 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22892284     DOI: 10.1016/j.jaad.2012.06.034

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  11 in total

1.  The MPATH-Dx reporting schema for melanocytic proliferations and melanoma.

Authors:  Michael W Piepkorn; Raymond L Barnhill; David E Elder; Stevan R Knezevich; Patricia A Carney; Lisa M Reisch; Joann G Elmore
Journal:  J Am Acad Dermatol       Date:  2013-10-28       Impact factor: 11.527

2.  Pathologist characteristics associated with accuracy and reproducibility of melanocytic skin lesion interpretation.

Authors:  David E Elder; Michael W Piepkorn; Raymond L Barnhill; Gary M Longton; Heidi D Nelson; Stevan R Knezevich; Margaret S Pepe; Patricia A Carney; Linda J Titus; Tracy Onega; Anna N A Tosteson; Martin A Weinstock; Joann G Elmore
Journal:  J Am Acad Dermatol       Date:  2018-03-07       Impact factor: 11.527

3.  Evaluating the Impact of Formal Dermatopathology Fellowship Training on Practice Patterns and Characteristics Among Dermatologists Submitting Claims for Medicare Pathology Examinations in 2017.

Authors:  Christian Gronbeck; Philip E Kerr; Hao Feng
Journal:  J Clin Aesthet Dermatol       Date:  2022-08

4.  Pathologists' Use of Second Opinions in Interpretation of Melanocytic Cutaneous Lesions: Policies, Practices, and Perceptions.

Authors:  Berta M Geller; Paul D Frederick; Stevan R Knezevich; Jason P Lott; Heidi D Nelson; Linda J Titus; Patricia A Carney; Anna N A Tosteson; Tracy L Onega; Raymond L Barnhill; Martin A Weinstock; David E Elder; Michael W Piepkorn; Joann G Elmore
Journal:  Dermatol Surg       Date:  2018-02       Impact factor: 3.398

5.  Second opinion in breast pathology: policy, practice and perception.

Authors:  Berta M Geller; Heidi D Nelson; Patricia A Carney; Donald L Weaver; Tracy Onega; Kimberly H Allison; Paul D Frederick; Anna N A Tosteson; Joann G Elmore
Journal:  J Clin Pathol       Date:  2014-07-22       Impact factor: 3.411

6.  Improved cytodiagnostics and quality of patient care through double reading of selected cases by an expert cytopathologist.

Authors:  Chantal C H J Kuijpers; Mike Visser; Daisy M D S Sie-Go; Henk de Leeuw; Mathilda J de Rooij; Paul J van Diest; Mehdi Jiwa
Journal:  Virchows Arch       Date:  2015-03-17       Impact factor: 4.064

7.  MicroRNA Ratios Distinguish Melanomas from Nevi.

Authors:  Rodrigo Torres; Ursula E Lang; Miroslav Hejna; Samuel J Shelton; Nancy M Joseph; A Hunter Shain; Iwei Yeh; Maria L Wei; Michael C Oldham; Boris C Bastian; Robert L Judson-Torres
Journal:  J Invest Dermatol       Date:  2019-09-30       Impact factor: 8.551

8.  Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model.

Authors:  Rami N Al-Rohil; Jessica L Moore; Nathan Heath Patterson; Sarah Nicholson; Nico Verbeeck; Marc Claesen; Jameelah Z Muhammad; Richard M Caprioli; Jeremy L Norris; Sara Kantrow; Margaret Compton; Jason Robbins; Ahmed K Alomari
Journal:  J Cutan Pathol       Date:  2021-07-02       Impact factor: 1.587

9.  Routine Clinical-Pathologic Correlation of Pigmented Skin Tumors Can Influence Patient Management.

Authors:  Caterina Longo; Simonetta Piana; Aimilios Lallas; Elvira Moscarella; Mara Lombardi; Margherita Raucci; Giovanni Pellacani; Giuseppe Argenziano
Journal:  PLoS One       Date:  2015-09-01       Impact factor: 3.240

10.  Comparing whole slide digital images versus traditional glass slides in the detection of common microscopic features seen in dermatitis.

Authors:  Nikki S Vyas; Michael Markow; Carlos Prieto-Granada; Sudeep Gaudi; Leslie Turner; Paul Rodriguez-Waitkus; Jane L Messina; Drazen M Jukic
Journal:  J Pathol Inform       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.